EMA turns down gene therapy on appeal

The European Medicines Agency has reaffirmed its decision not to recommend the gene therapy, Glybera, for marketing following an appeal from the developer, Amsterdam Molecular Therapeutics BV. This is the second gene therapy to be turned down by the EMA.